PH12014501052B1 - Methods and compositions for the treatment of diabetes and related symptoms - Google Patents

Methods and compositions for the treatment of diabetes and related symptoms

Info

Publication number
PH12014501052B1
PH12014501052B1 PH1/2014/501052A PH12014501052A PH12014501052B1 PH 12014501052 B1 PH12014501052 B1 PH 12014501052B1 PH 12014501052 A PH12014501052 A PH 12014501052A PH 12014501052 B1 PH12014501052 B1 PH 12014501052B1
Authority
PH
Philippines
Prior art keywords
diabetes
compositions
treatment
related symptoms
glutamine
Prior art date
Application number
PH1/2014/501052A
Other languages
English (en)
Other versions
PH12014501052A1 (en
Inventor
Yutaka Niihara
Original Assignee
Emmaus Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48470183&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12014501052(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Emmaus Medical Inc filed Critical Emmaus Medical Inc
Publication of PH12014501052A1 publication Critical patent/PH12014501052A1/en
Publication of PH12014501052B1 publication Critical patent/PH12014501052B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
PH1/2014/501052A 2011-11-21 2012-11-17 Methods and compositions for the treatment of diabetes and related symptoms PH12014501052B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161629633P 2011-11-21 2011-11-21
PCT/US2012/000557 WO2013077893A1 (en) 2011-11-21 2012-11-17 Methods and compositions for the treatment of diabetes and related symptoms

Publications (2)

Publication Number Publication Date
PH12014501052A1 PH12014501052A1 (en) 2014-06-30
PH12014501052B1 true PH12014501052B1 (en) 2020-10-09

Family

ID=48470183

Family Applications (2)

Application Number Title Priority Date Filing Date
PH1/2014/501052A PH12014501052B1 (en) 2011-11-21 2012-11-17 Methods and compositions for the treatment of diabetes and related symptoms
PH1/2020/550726A PH12020550726B1 (en) 2011-11-21 2012-11-17 Method and compositions for the treatment of diabetes and related symptoms

Family Applications After (1)

Application Number Title Priority Date Filing Date
PH1/2020/550726A PH12020550726B1 (en) 2011-11-21 2012-11-17 Method and compositions for the treatment of diabetes and related symptoms

Country Status (10)

Country Link
US (2) US20130143968A1 (cg-RX-API-DMAC7.html)
EP (2) EP2782588B1 (cg-RX-API-DMAC7.html)
JP (4) JP6089042B2 (cg-RX-API-DMAC7.html)
CN (3) CN108354916A (cg-RX-API-DMAC7.html)
BR (1) BR112014011898A2 (cg-RX-API-DMAC7.html)
ES (1) ES2785094T3 (cg-RX-API-DMAC7.html)
HK (1) HK1257401A1 (cg-RX-API-DMAC7.html)
IN (1) IN2014KN01037A (cg-RX-API-DMAC7.html)
PH (2) PH12014501052B1 (cg-RX-API-DMAC7.html)
WO (1) WO2013077893A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
CN111295187A (zh) 2017-08-14 2020-06-16 胺细拉健康公司 用于治疗肝脏疾病的氨基酸组合物
AR115585A1 (es) 2018-06-20 2021-02-03 Axcella Health Inc Composiciones y métodos para el tratamiento de la infiltración de grasa en músculo

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6031000A (en) * 1998-06-23 2000-02-29 Iowa State University Research Foundation, Inc. Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
WO2003072556A1 (en) * 2001-06-27 2003-09-04 Prosidion Ltd. Glutaminyl based dpiv inhibitors
SE0201713D0 (sv) * 2001-11-23 2002-06-06 Gramineer Internat Ab New methods and use III
TWI351278B (en) * 2002-03-01 2011-11-01 Nisshin Pharma Inc Agent for preventing and treating of liver disease
US20070025953A1 (en) * 2005-07-27 2007-02-01 Jones Michael R Co-therapy for diabetic conditions
CN101472579B (zh) * 2006-04-22 2013-07-03 霍利斯-伊登医药公司 药物和用途
EP2077110A4 (en) * 2006-09-29 2012-06-27 Ajinomoto Kk GLUTAMINE-CONTAINING COMPOSITION FOR INCREASING BLOOD FLOW
US20080221074A1 (en) * 2006-11-17 2008-09-11 Jaime Flores-Riveros Drug Screen and Treatment Method
EP2057905A1 (en) * 2007-11-12 2009-05-13 TIMA Foundation Composition for moderating Triglyceride and Cholesterol Levels
KR20110120866A (ko) * 2009-01-12 2011-11-04 바이오키어 인코포레이티드 당뇨병 치료 조성물 및 치료방법
NL1036746C2 (nl) * 2009-03-20 2010-09-21 Glnp Holding B.V. Kit van onderdelen bevattende l-glutamine en egcg.
BR112012006437A2 (pt) * 2009-09-23 2016-04-19 Biokier Inc composições e métodos para tratamento do diabetes e outros distúrbios

Also Published As

Publication number Publication date
IN2014KN01037A (en) 2015-10-09
CN103945858A (zh) 2014-07-23
WO2013077893A1 (en) 2013-05-30
CN108354916A (zh) 2018-08-03
HK1257401A1 (zh) 2019-10-18
JP6389495B2 (ja) 2018-09-12
EP2782588B1 (en) 2020-04-15
JP2014533689A (ja) 2014-12-15
JP2017052766A (ja) 2017-03-16
PH12014501052A1 (en) 2014-06-30
US20190192463A1 (en) 2019-06-27
BR112014011898A2 (pt) 2017-05-16
PH12020550726B1 (en) 2022-11-09
EP2782588A1 (en) 2014-10-01
EP3437649A1 (en) 2019-02-06
JP2018115175A (ja) 2018-07-26
PH12020550726A1 (en) 2021-06-14
JP2018199692A (ja) 2018-12-20
CN108478551A (zh) 2018-09-04
ES2785094T3 (es) 2020-10-05
EP2782588A4 (en) 2015-05-20
US20130143968A1 (en) 2013-06-06
JP6089042B2 (ja) 2017-03-01
JP6550160B2 (ja) 2019-07-24

Similar Documents

Publication Publication Date Title
UA114726C2 (uk) 1,4-дизаміщені аналоги піридазину та способи лікування пов'язаних з дефіцитом smn станів
WO2010080756A3 (en) Harmine derivatives for reducing body weight
PH12015501108A1 (en) Treatment of pulmonary disease
TN2014000122A1 (en) 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases
MY173877A (en) Branched 3-phenylpropionic acid derivatives and the use thereof
MX351464B (es) El uso de un agonista del receptor 8 tipo toll para el tratamiento de enfermedades alérgicas.
PH12015501291B1 (en) Functionalized exendin-4 derivatives
UA110983C2 (uk) Похідна 1,2,3,4-тетрагідрохіноліну, придатна для лікування діабету
MX2015007916A (es) Peri-carbinoles.
MX2013011691A (es) Inhibidores de la replicacion viral, su proceso de preparacion y sus usos terapeuticos.
MX2015009444A (es) Trampas novedosas en el tratamiento de la degeneracion macular.
MX367811B (es) D-metadona para el tratamiento de síntomas psiquiátricos.
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
EA201690327A1 (ru) Терапевтические способы
IN2014KN01255A (en) Methods and compositions for the treatment of diverticulosis
PH12020550726A1 (en) Method and compositions for the treatment of diabetes and related symptoms
NZ707773A (en) Methods of treating liver diseases
UA113859C2 (xx) Похідні спіротієнопіранпіперидину як антагоністи рецептора orl-1 для їх застосування при лікуванні алкогольної залежності та зловживання алкоголем
PH12014500577A1 (en) Sulfonic acid salts of heterocyclylamide-substituted imidazoles
PH12012501476A1 (en) Aminoquinoline derivatives
MX2021014120A (es) Tratamiento de los sintomas asociados a terapia privacion de androgenos.
MX2014006990A (es) Tratamiento para diabetes tipo i y tipo ii.
TN2013000150A1 (en) Co-crystals and salts of ccr3-inhibitors